112 related articles for article (PubMed ID: 17520176)
1. Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.
Feldman DR; Kondagunta GV; Ginsberg MS; Ishill N; Patil S; Cestaro J; Obbens E; Sheinfeld J; Bosl GJ; Motzer RJ
Invest New Drugs; 2007 Oct; 25(5):487-90. PubMed ID: 17520176
[TBL] [Abstract][Full Text] [Related]
2. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Multi-Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma.
Burotto M; Edgerly M; Velarde M; Balasubramaniam S; Drabkin H; Gormaz JG; O'Sullivan C; Madan R; Fojo T
Oncologist; 2017 Aug; 22(8):888-e84. PubMed ID: 28679644
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors.
Rivera E; Lee J; Davies A
Oncologist; 2008 Dec; 13(12):1207-23. PubMed ID: 19088324
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
Low JA; Wedam SB; Lee JJ; Berman AW; Brufsky A; Yang SX; Poruchynsky MS; Steinberg SM; Mannan N; Fojo T; Swain SM
J Clin Oncol; 2005 Apr; 23(12):2726-34. PubMed ID: 15837987
[TBL] [Abstract][Full Text] [Related]
6. A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane.
Ajani JA; Safran H; Bokemeyer C; Shah MA; Lenz HJ; Van Cutsem E; Burris HA; Lebwohl D; Mullaney B
Invest New Drugs; 2006 Sep; 24(5):441-6. PubMed ID: 16586011
[TBL] [Abstract][Full Text] [Related]
7. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer.
Steinberg M
Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
Liu G; Chen YH; Dipaola R; Carducci M; Wilding G
Clin Genitourin Cancer; 2012 Jun; 10(2):99-105. PubMed ID: 22386239
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.
Jacobs S; Fox E; Krailo M; Hartley G; Navid F; Wexler L; Blaney SM; Goodwin A; Goodspeed W; Balis FM; Adamson PC; Widemann BC
Clin Cancer Res; 2010 Jan; 16(2):750-4. PubMed ID: 20068084
[TBL] [Abstract][Full Text] [Related]
10. Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors.
Maroto P; Huddart R; Garcia del Muro X; Horwich A; Paz Ares L; Aparicio J; Germa-Lluch JR
Oncology; 2011; 80(3-4):219-22. PubMed ID: 21734411
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan.
Aogi K; Rai Y; Ito Y; Masuda N; Watanabe J; Horiguchi J; Tokudome T; Takashima S
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1427-33. PubMed ID: 23536163
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
Shimizu T; Yamamoto N; Yamada Y; Fujisaka Y; Yamada K; Fujiwara Y; Takayama K; Tokudome T; Klimovsky J; Tamura T
Cancer Chemother Pharmacol; 2008 Apr; 61(5):751-8. PubMed ID: 17594093
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer.
Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E
Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153
[TBL] [Abstract][Full Text] [Related]
15. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
16. An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors.
Oechsle K; Honecker F; Kollmannsberger C; Rick O; Grünwald V; Mayer F; Hartmann JT; Bokemeyer C
Anticancer Drugs; 2007 Mar; 18(3):273-6. PubMed ID: 17264758
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma.
Posadas EM; Undevia S; Manchen E; Wade JL; Colevas AD; Karrison T; Vokes EE; Stadler WM
Cancer Biol Ther; 2007 Apr; 6(4):490-3. PubMed ID: 17457044
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes.
Denduluri N; Low JA; Lee JJ; Berman AW; Walshe JM; Vatas U; Chow CK; Steinberg SM; Yang SX; Swain SM
J Clin Oncol; 2007 Aug; 25(23):3421-7. PubMed ID: 17606971
[TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy.
Vansteenkiste J; Lara PN; Le Chevalier T; Breton JL; Bonomi P; Sandler AB; Socinski MA; Delbaldo C; McHenry B; Lebwohl D; Peck R; Edelman MJ
J Clin Oncol; 2007 Aug; 25(23):3448-55. PubMed ID: 17606973
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.
Bhushan S; Walko CM
Ann Pharmacother; 2008 Sep; 42(9):1252-61. PubMed ID: 18648018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
